Q-omics provides the consensus-scored TP73 profile across patient tissues and cancer cell-line models. TP73 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TP73 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, TP73 RNA expression shows 16,980 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, KIRC, and THYM as cancer lineages where TP73 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TP73 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TP73 survival associations across molecular data types. TP73 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TP73 RNA expression–survival associations across cancer types. High TP73 expression shows unfavorable associations in ACC, THCA, KIRP and LGG, but favorable associations in HNSC and READ. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TP73 RNA expression.
This table summarizes TP73 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TP73. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TP73 shows higher tumor expression in KIRC, KIRP, COAD, LIHC, LUSC and BLCA. The KIRC box plot shows higher TP73 RNA expression in tumor versus normal tissue (log2 FC = +0.766, t-test p < 0.001).
This table shows molecular features associated with TP73 in patient tissues and cancer cell lines. In patient samples, TP73 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TP73 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
